IDT

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.

The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.